Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization : A real world experience.
CONCLUSIONS: This retrospective analysis in a real world situation of medium to high-risk ACS patients undergoing invasive revascularization confirmed the results of most large-scale randomized trials by demonstrating reduced bleeding rates in favor of bivalirudin vs. UFH + GPI but with no significant differences between treatment strategies for long-term all-cause and cardiovascular mortality.
PMID: 27624328 [PubMed - as supplied by publisher] (Source: Wiener Klinische Wochenschrift)
Source: Wiener Klinische Wochenschrift - September 12, 2016 Category: Journals (General) Authors: Rohla M, Tentzeris I, Freynhofer MK, Farhan S, Jarai R, Egger F, Weiss TW, Wojta J, Geppert A, Kastrati A, Stone GW, Huber K Tags: Wien Klin Wochenschr Source Type: research
Pooled Analysis Comparing the Efficacy of Intracoronary vs. Intravenous Abciximab in Smokers Versus Non-Smokers undergoing Primary Percutaneous Coronary Revascularization for Acute ST-Elevation Myocardial Infarction
Cigarette smokers with ST-segment elevation myocardial infarction (STEMI) may present different response to potent antithrombotic therapy compared with non-smokers. We assessed the impact of smoking status and intracoronary abciximab in patients with STEMI undergoing primary percutaneous coronary intervention (PCI). We pooled data from 5 randomized trials comparing intracoronary versus intravenous abciximab bolus in patients undergoing primary PCI. The primary endpoint was the composite of death or reinfarction at a mean follow-up of 292 ±138 days. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - September 12, 2016 Category: Cardiology Authors: Raffaele Piccolo, Gennaro Galasso, Ingo Eitel, Alberto Dominguez-Rodriguez, Allan Zeeberg Iversen, Youlan L. Gu, Pedro Abreu-Gonzalez, Bart JGL. de Smet, Giovanni Esposito, Stephan Windecker, Holger Thiele, Federico Piscione Source Type: research
Successful Endovascular Management of Massive Pansinus Thrombosis: Case Report and Review of Literature
We present the case of a 9-day-old infant, who presented in coma and was treated successfully with a combination of mechanical thrombectomy using the MindFrame System via the right jugular vein, local infusion of recombinant tissue plasminogen activator and abciximab, as well as anticoagulation. In this case, aggressive thrombectomy and thrombolysis achieved complete neurologic restoration safely and quickly.Pediatr Neurosurg (Source: Pediatric Neurosurgery)
Source: Pediatric Neurosurgery - August 31, 2016 Category: Neurosurgery Source Type: research
Intraprocedural abciximab bolus versus pretreatment oral dual antiplatelet medication for endovascular stenting of unruptured intracranial aneurysms
Conclusions
Standalone intraprocedural abciximab bolus was not associated with an increased rate of complications compared with pretreatment with DAPM for unruptured intracranial aneurysm stenting. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - August 11, 2016 Category: Neurosurgery Authors: Levitt, M. R., Moon, K., Albuquerque, F. C., Mulholland, C. B., Kalani, M. Y. S., McDougall, C. G. Tags: Hemorrhagic stroke Source Type: research
Intracoronary Abciximab in Diabetic STEMI Patients Questionable Benefit, Proven Harm ∗
Rapid and sustained restoration of antegrade flow through the epicardial coronary artery is the primary goal of current treatment of acute ST-segment elevation myocardial infarction (STEMI). It consists of a combination of mechanical recanalization of the occluded artery with primary percutaneous coronary intervention (PCI) and aggressive antithrombotic therapy, which is directed at preventing thrombus growth, mitigating distal embolization, and preventing thrombosis in the implanted coronary stent. In the early days of PCI, reocclusion of the reperfused infarct-related artery occurred frequently. In those days, glycopro...
Source: Journal of the American College of Cardiology - August 9, 2016 Category: Cardiology Source Type: research
1-Year Outcomes With Intracoronary Abciximab in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention
ConclusionsIn diabetic patients with STEMI, the administration of intracoronary abciximab improved the effectiveness of primary PCI compared with the intravenous bolus. (Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - August 9, 2016 Category: Cardiology Source Type: research
How abciximab might be clinically useful
Platelet aggregation is a crucial feature in coronary artery thrombus formation and is a major causative factor in both acute coronary syndromes (ACS) and reocclusion after percutaneous coronary interventions (PCI). The glycoprotein (GP) IIb/IIIa ( αIIbβ3) integrin receptor is the pivotal mediator of platelet aggregation. In late 1990s, the introduction of GP IIb/IIIa inhibitors (GPI) was associated with a reduction of ischemic complication, and a clear clinical benefit in PCI during ACS, for both non ST-elevation (NSTE) and ST-segment eleva tion myocardial infarction (STEMI). (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - August 3, 2016 Category: Cardiology Authors: Co şkun Usta, Nur Tükel Turgut, Aslı Bedel Tags: Review Source Type: research
Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction
Conclusion: Prasugrel loading dose was associated with a lower percentage of cross-sections with residual thrombus area more than 10% as compared with both clopidogrel and ticagrelor, although intrastent thrombus volume was not significantly different between prasugrel and ticagrelor.
The frequency of MBG 3 was the only reperfusion index that was significantly more prevalent in prasugrel treated group as compared with clopidogrel and ticagrelor groups. (Source: Journal of Cardiovascular Medicine)
Source: Journal of Cardiovascular Medicine - July 30, 2016 Category: Cardiology Tags: Original articles Source Type: research
O-034 Abciximab Therapy for Thromboembolic Complications of Neuroendovascular Procedures
ConclusionAbciximab administration is an effective method of treating thromboembolic complications of neuroendovascular procedures. Angiographic outcomes were not appreciably different between different routes of abciximab administration. Infarction was least common in patients treated with IA abciximab; the addition of postoperative abciximab infusion did not affect the rate of infarction. No or partial angiographic improvement was associated with significantly higher rates of postoperative infarction than complete angiographic improvement.DisclosuresA. Kansagra: None. T. Madaelil: None. D. Cross: None. C. Moran: 2; C; Me...
Source: Journal of NeuroInterventional Surgery - July 28, 2016 Category: Neurosurgery Authors: Kansagra, A., Madaelil, T., Cross, D., Moran, C., Derdeyn, C. Tags: Oral abstracts Source Type: research
P-001 Permanent Implantation of the Solitaire Device as a Bailout Technique for Large Vessel Intracranial Occlusions
ConclusionWith the recent over-whelming evidence demonstrating the effectiveness endovascular therapy in acute ischemic stroke, the expansion of stroke therapy requires that a variety of techniques be available to the operators. Permanent implantation of the Solitaire stent achieves adequate distal flow and good clinical outcomes in the setting of AIS. This case series suggests this technique provides a safe alternative for difficult cases refractory to other revascularization techniques.Key Wordsstroke, revascularization, stentDisclosuresJ. Houde: None. E. Barber: None. M. Kelly: 2; C; Medtronic. 4; C; Blockade. 6; C; Pen...
Source: Journal of NeuroInterventional Surgery - July 28, 2016 Category: Neurosurgery Authors: Houde, J., Barber, E., Kelly, M., Peeling, L. Tags: Oral poster abstracts Source Type: research
P-016 Successful Flow Diversion of Cerebral Aneurysms in Plavix Hyporesponders (PRU >= 200): An Argument for Antiplatelet Monotherapy?
ConclusionsHyporesponse to Plavix (PRU ≥ 200) is not a contraindication to aneurysm treatment with the PED in patients on a standard dual antiplatelet regimen of Aspirin 325 mg and Plavix 75 mg daily. These data suggest a diminutive role of Plavix in preventing thrombotic complications during these procedures.DisclosuresG. Colby: 1; C; Stryker, Medtronic. 2; C; Microvention. L. Lin: 1; C; Stryker. D. Lubelski: None. M. Bender: None. R. Xu: None. B. Jiang: None. J. Huang: None. R. Tamargo: None. A. Coon: 1; C; Sequent. 2; C; Stryker, Medtronic, Microvention, Sequent. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - July 28, 2016 Category: Neurosurgery Authors: Colby, G., Lin, L., Lubelski, D., Bender, M., Xu, R., Jiang, B., Huang, J., Tamargo, R., Coon, A. Tags: Oral poster abstracts Source Type: research
E-065 "Rescue" Intracranial Stenting for Refractory Large Vessel (Re)occlusion in Acute Ischemic Stroke
ConclusionIntracranial stent placement for refractory large vessel (re)occlusion in acute ischemic stroke is feasible with high technical success rate, however, this is not always associated with favorable clinical outcome. If refractory vessel occlusion or reocclusion is encountered during acute stroke intervention, early stent placement and recanalization may lead to more favorable outcome. Verification in a larger cohort is necessary.DisclosuresG. Toth: None. S. John: None. M. Elgabaly: None. M. Hussain: None. M. Bain: None. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - July 28, 2016 Category: Neurosurgery Authors: Toth, G., John, S., Elgabaly, M., Hussain, M., Bain, M. Tags: Electronic poster abstracts Source Type: research
Rare Case of Intradural Haematoma and Paralysis Following Abciximab for ST Elevation Acute Coronary Syndrome
We present the case of a previously healthy 64-year-old male who presented initially with chest pain and inferior ST elevation acute coronary syndrome. Primary angiography revealed minor left coronary disease and occluded proximal right coronary artery. Oral loading doses of aspirin 300mg and prasugrel 60mg were prescribed. Given significant thrombotic burden, weight-adjusted abciximab (0.25mg/kg) and unfractionated heparin (70 units /kg) boluses were given and a 6Fr Export aspiration catheter restored TIMI III flow. (Source: Heart, Lung and Circulation)
Source: Heart, Lung and Circulation - July 27, 2016 Category: Cardiology Authors: G. Wong, D. Scherer, A. Nelson, Roberts-R. Thomson, S. Parvar, A. Pisaniello, M. Worthley Tags: 451 Source Type: research
Abciximab as a bridging strategy to overcome morphine –prasugrel interaction in STEMI patients
ConclusionThe infusion of the GPIIb/IIIa receptor blocker abciximab allows immediate and efficient platelet inhibition in STEMI patients concomitantly receiving the oral ADP receptor blocker prasugrel and morphine. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - July 23, 2016 Category: Drugs & Pharmacology Authors: Jolanta M. Siller ‐Matula, Simon Specht, Jacek Kubica, Dimitrios Alexopoulos, Raffaele De Caterina, Eva‐Luise Hobl, Bernd Jilma, Günter Christ, Irene M. Lang Tags: DRUG INTERACTIONS Source Type: research
